FDA authorizes ZYN nicotine pouches as lower‑risk alternative to cigarettes

The U.S. Food and Drug Administration issued Modified Risk Tobacco Product (MRTP) orders for 20 ZYN nicotine‑pouch products made by Swedish Match USA, a subsidiary of Philip Morris International. The authorization covers ten flavors in 3 mg and 6 mg nicotine strengths and permits the marketing claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.”

This is the first MRTP order granted for nicotine pouches. The FDA said the scientific review showed the claim is accurate, that adult consumers understand it, and that the marketing would benefit public health, while noting that no tobacco product is safe. The agency requires post‑market surveillance and behavioral studies and may revoke the order if youth usage rises. Philip Morris U.S. CEO Stacey Kennedy called the decision a “important moment for the more than 45 million legal‑age nicotine consumers in America.”

The FDA’s action does not constitute a safety endorsement; it merely allows a relative‑risk statement compared with combustible cigarettes.